Developer docs
API playgroundTry for free, no card

Search company profiles

Randis Pharmaceutical Development Institute

Full company profile

uuid003gz4g

Namestring
Randis Pharmaceutical Development Institute
Legal namestring
株式会社Randis医薬開発研究所
Websiteurl
randis.co.jp
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Randis Pharmaceutical Development Institute is a privately held Japanese pharmaceutical R&D company incorporated on February 3, 2023, and headquartered in Nagoya, Aichi Prefecture. Under Representative Director and CEO Muramatsu Naomi, it operates three distinct business lines: in-house pharmaceutical product development with a focus on cancer gene therapy; R&D support services providing outsourced powder-inhalation drug development for lung-disease programs; and consulting services around Drug Delivery System (DDS) technology. The company targets pharmaceutical developers and research organizations seeking specialized gene-therapy and inhalation-formulation capabilities, including international counterparties as signaled by the launch of an English-language corporate website.

The company's disclosed technology core is dry-powder gene delivery, applied both to its own pipeline and to client programs. Its flagship disclosed research asset is p53 Dry Gene Powder, a gene therapy candidate being developed for Malignant Pleural Mesothelioma (MPM). The R&D support line applies the same inhalation/powder-formulation expertise on a contract basis to external developers working on pulmonary indications, while the consulting line monetizes DDS advisory know-how. No patents, peer-reviewed publications, named research collaborators, or headcount figures are disclosed, so the maturity of the underlying science base is not externally verifiable.

The business model combines three revenue pathways: long-dated upside from proprietary drug development (contingent on future licensing, partnership, or commercialization milestones), fee-for-service contract R&D for powder-inhalation programs, and consulting revenue from DDS technology engagements. Pricing structures, contract terms, customer identities, and revenue figures are not publicly disclosed, and the English-language site remains largely in a 'Coming Soon' state, indicating that international commercial activity has not yet commenced. As a result, the company's near-term financial trajectory is currently unobservable from public information.

Short descriptiontext

Randis Pharmaceutical Development Institute is a Nagoya-based Japanese pharmaceutical R&D startup founded in February 2023 that develops cancer gene therapies (including p53 Dry Gene Powder for Malignant Pleural Mesothelioma), offers powder-inhalation drug development outsourcing for lung-disease programs, and provides DDS technology consulting.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersNishiku, Japan
HQ citystring
Nishiku
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical R&D services, cancer gene therapy, inhalation drug development, drug delivery consulting, contract research services
Industry3 codes
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing32541
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceutical R&D Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical R&D Services
TypeProfessional Services
Description

Pharmaceutical product development and experimental equipment R&D services.

randis.co.jp
2R&D Outsourcing Services
TypeProfessional Services
Description

Contracted research and development services for third parties.

randis.co.jp
3R&D Consulting Services
TypeProfessional Services
Description

Research and development consulting services including DDS technology implementation.

randis.co.jp
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Randis Pharmaceutical Development Institute conducts development of novel cancer gene therapy drugs (including a p53 Dry Gene Powder for malignant pleural mesothelioma) and provides contracted R&D services for powder inhalation formulations of low-molecular-weight compounds and nucleic acids targeting lung diseases. It also offers consulting services on Drug Delivery System (DDS) technology adoption, particularly for administration route optimization.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Randis Pharmaceutical Development Institute operates three core business divisions: Pharmaceutical Product Developments (new cancer gene therapy drugs including p53 Dry Gene Powder), R&D Support Services (inhalation drug development contracting for lung diseases using powdered formulations), and R&D Consulting Services (DDS technology consulting for drug administration routes). The company focuses on advanced drug delivery and gene therapy research.

Product and service4 records
1Pharmaceutical Product Developments (医薬品開発事業)
CategoryPharmaceutical R&D
Description

In-house development of novel cancer gene therapy drugs, including research on p53 Dry Gene Powder for malignant pleural mesothelioma (MPM). Targeted at pharmaceutical companies and research institutions seeking innovative cancer gene therapy approaches.

2R&D Support Services — Inhalation Drug Development (吸入剤開発受託事業)
CategoryContract Pharmaceutical R&D
Description

Contracted development of powdered inhalation formulations of low-molecular-weight compounds and nucleic acids for lung disease treatments. Supports small-lot experimental development for pharmaceutical companies and research organizations.

3R&D Consulting Services (コンサルティング事業)
CategoryPharmaceutical Consulting
Description

Development consulting for Drug Delivery System (DDS) technology implementation, with a focus on optimizing drug administration routes for pharmaceutical developers facing formulation challenges.

4p53 Dry Gene Powder
CategoryResearch-stage Pharmaceutical Product
Description

Dry gene powder formulation under development for cancer gene therapy; research results announced in March 2023 showed suppression of malignant pleural mesothelioma (MPM).

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Takara Bio Inc.
TypeBroad incumbent
Description

Established Japanese biotech offering gene therapy CDMO services, viral vector production, and regenerative medicine products. A larger incumbent operating in the same gene therapy and nucleic acid handling domain as Randis.

TypeBroad incumbent
Description

Global CDMO with significant inhalation formulation expertise, including particle engineering for dry powder inhalers. Comparable to Randis's inhalation development service line but at substantially greater scale and with broader pharma customer base.

TypeBroad incumbent
Description

Japan's largest CRO offering pharmaceutical development, clinical operations, and CDMO services. A broad incumbent against which Randis's CRO/consulting offering competes for Japanese pharma R&D outsourcing budgets.

TypeEmerging player
Description

Specialist in aerosol drug delivery technology for respiratory pharmaceuticals, with a focus on vibrating mesh nebulizer platforms. Comparable to Randis's inhalation development work, though with a more device-centric and acute-care focus.

5Curalogic
TypeEmerging player
Description

Specialty drug delivery company focused on inhaled peptide and small-molecule therapies for respiratory disease. Comparable emerging player targeting the same small-lot inhalation formulation niche that Randis serves with its R&D Support Services.

TypeDirect peer
Description

Specialist inhalation drug delivery company (now part of Philip Morris International) with deep expertise in powder formulation and small-molecule/nebulized therapies. Direct peer to Randis's R&D Support Services business for lung disease inhalation development.

7Noile-Immune Biotech
TypeDirect peer
Description

Japanese clinical-stage gene therapy company focused on CAR-T and solid tumor gene-modified cell therapies. Comparable to Randis as a Japan-based, oncology-focused gene therapy developer.

8AnGes, Inc.
TypeDirect peer
Description

Japanese gene therapy company that developed an MPM gene therapy candidate (MG011) using a similar intrapleural administration approach. Direct peer to Randis's p53 Dry Gene Powder program and the only publicly known Japanese peer also targeting MPM with gene therapy.

TypeBroad incumbent
Description

Major global pharmaceutical services company with inhalation development, soft mist, and biologic manufacturing capabilities. Broad incumbent offering overlapping inhalation and biologics services that compete with Randis's CRO offering.

TypeEmerging player
Description

Clinical-stage nucleic acid therapeutics company developing saRNA and mRNA products, including inhaled/LNP-enabled programs. Comparable emerging player at the intersection of nucleic acid chemistry and respiratory delivery that Randis also targets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Randis Pharmaceutical Development Institute

Pharmaceutical R&D Servicesrandis.co.jp

Randis Pharmaceutical Development Institute is a Nagoya-based Japanese pharmaceutical R&D startup founded in February 2023 that develops cancer gene therapies (including p53 Dry Gene Powder for Malignant Pleural Mesothelioma), offers powder-inhalation drug development outsourcing for lung-disease programs, and provides DDS technology consulting.

What Randis Pharmaceutical Development Institute does

Randis Pharmaceutical Development Institute is a privately held Japanese pharmaceutical R&D company incorporated on February 3, 2023, and headquartered in Nagoya, Aichi Prefecture. Under Representative Director and CEO Muramatsu Naomi, it operates three distinct business lines: in-house pharmaceutical product development with a focus on cancer gene therapy; R&D support services providing outsourced powder-inhalation drug development for lung-disease programs; and consulting services around Drug Delivery System (DDS) technology. The company targets pharmaceutical developers and research organizations seeking specialized gene-therapy and inhalation-formulation capabilities, including international counterparties as signaled by the launch of an English-language corporate website.

The company's disclosed technology core is dry-powder gene delivery, applied both to its own pipeline and to client programs. Its flagship disclosed research asset is p53 Dry Gene Powder, a gene therapy candidate being developed for Malignant Pleural Mesothelioma (MPM). The R&D support line applies the same inhalation/powder-formulation expertise on a contract basis to external developers working on pulmonary indications, while the consulting line monetizes DDS advisory know-how. No patents, peer-reviewed publications, named research collaborators, or headcount figures are disclosed, so the maturity of the underlying science base is not externally verifiable.

The business model combines three revenue pathways: long-dated upside from proprietary drug development (contingent on future licensing, partnership, or commercialization milestones), fee-for-service contract R&D for powder-inhalation programs, and consulting revenue from DDS technology engagements. Pricing structures, contract terms, customer identities, and revenue figures are not publicly disclosed, and the English-language site remains largely in a 'Coming Soon' state, indicating that international commercial activity has not yet commenced. As a result, the company's near-term financial trajectory is currently unobservable from public information.

Randis Pharmaceutical Development Institute firmographics

Firmographics
Name
Randis Pharmaceutical Development Institute
Legal name
株式会社Randis医薬開発研究所
Website
https://randis.co.jp
Company type
Private
Founded year
2023
Operating status
Operating
Short description
Randis Pharmaceutical Development Institute is a Nagoya-based Japanese pharmaceutical R&D startup founded in February 2023 that develops cancer gene therapies (including p53 Dry Gene Powder for Malignant Pleural Mesothelioma), offers powder-inhalation drug development outsourcing for lung-disease programs, and provides DDS technology consulting.
Ownership category
akta.pro rank

Randis Pharmaceutical Development Institute industry classification

Industry
Product category
Pharmaceutical R&D Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Pharmaceutical R&D services
  • Cancer gene therapy
  • Inhalation drug development
  • Drug delivery consulting
  • Contract research services

Where Randis Pharmaceutical Development Institute is headquartered

Location

Headquarters

HQ city
Nishiku
HQ country
Japan
HQ region
Asia

Offices1 record

Markets served

Randis Pharmaceutical Development Institute business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical R&D Services: Pharmaceutical product development and experimental equipment R&D services.
  2. R&D Outsourcing Services: Contracted research and development services for third parties.
  3. R&D Consulting Services: Research and development consulting services including DDS technology implementation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Randis Pharmaceutical Development Institute product offering

Product offering

Core offering

Randis Pharmaceutical Development Institute conducts development of novel cancer gene therapy drugs (including a p53 Dry Gene Powder for malignant pleural mesothelioma) and provides contracted R&D services for powder inhalation formulations of low-molecular-weight compounds and nucleic acids targeting lung diseases. It also offers consulting services on Drug Delivery System (DDS) technology adoption, particularly for administration route optimization.

Product overview

Randis Pharmaceutical Development Institute operates three core business divisions: Pharmaceutical Product Developments (new cancer gene therapy drugs including p53 Dry Gene Powder), R&D Support Services (inhalation drug development contracting for lung diseases using powdered formulations), and R&D Consulting Services (DDS technology consulting for drug administration routes). The company focuses on advanced drug delivery and gene therapy research.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceutical Product Developments (医薬品開発事業) In-house development of novel cancer gene therapy drugs, including research on p53 Dry Gene Powder for malignant pleural mesothelioma (MPM). Targeted at pharmaceutical companies and research institutions seeking innovative cancer gene therapy approaches.
  • R&D Support Services — Inhalation Drug Development (吸入剤開発受託事業) Contracted development of powdered inhalation formulations of low-molecular-weight compounds and nucleic acids for lung disease treatments. Supports small-lot experimental development for pharmaceutical companies and research organizations.
  • R&D Consulting Services (コンサルティング事業) Development consulting for Drug Delivery System (DDS) technology implementation, with a focus on optimizing drug administration routes for pharmaceutical developers facing formulation challenges.
  • p53 Dry Gene Powder Dry gene powder formulation under development for cancer gene therapy; research results announced in March 2023 showed suppression of malignant pleural mesothelioma (MPM).

Companies that use Randis Pharmaceutical Development Institute

Customer profile

Segments3 records

Ideal customer profiles3 records

Randis Pharmaceutical Development Institute technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Randis Pharmaceutical Development Institute partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves3 records

Expansion highlights3 records

Randis Pharmaceutical Development Institute competitors and assessment

Company assessment

Broad incumbents

  • Takara Bio Inc. Established Japanese biotech offering gene therapy CDMO services, viral vector production, and regenerative medicine products. A larger incumbent operating in the same gene therapy and nucleic acid handling domain as Randis.
  • Hovione: Global CDMO with significant inhalation formulation expertise, including particle engineering for dry powder inhalers. Comparable to Randis's inhalation development service line but at substantially greater scale and with broader pharma customer base.
  • CMIC Holdings: Japan's largest CRO offering pharmaceutical development, clinical operations, and CDMO services. A broad incumbent against which Randis's CRO/consulting offering competes for Japanese pharma R&D outsourcing budgets.
  • Catalent: Major global pharmaceutical services company with inhalation development, soft mist, and biologic manufacturing capabilities. Broad incumbent offering overlapping inhalation and biologics services that compete with Randis's CRO offering.

Emerging players

  • Aerogen: Specialist in aerosol drug delivery technology for respiratory pharmaceuticals, with a focus on vibrating mesh nebulizer platforms. Comparable to Randis's inhalation development work, though with a more device-centric and acute-care focus.
  • Curalogic: Specialty drug delivery company focused on inhaled peptide and small-molecule therapies for respiratory disease. Comparable emerging player targeting the same small-lot inhalation formulation niche that Randis serves with its R&D Support Services.
  • Arcturus Therapeutics: Clinical-stage nucleic acid therapeutics company developing saRNA and mRNA products, including inhaled/LNP-enabled programs. Comparable emerging player at the intersection of nucleic acid chemistry and respiratory delivery that Randis also targets.

Direct peers

  • Vectura Group: Specialist inhalation drug delivery company (now part of Philip Morris International) with deep expertise in powder formulation and small-molecule/nebulized therapies. Direct peer to Randis's R&D Support Services business for lung disease inhalation development.
  • Noile-Immune Biotech: Japanese clinical-stage gene therapy company focused on CAR-T and solid tumor gene-modified cell therapies. Comparable to Randis as a Japan-based, oncology-focused gene therapy developer.
  • AnGes, Inc. Japanese gene therapy company that developed an MPM gene therapy candidate (MG011) using a similar intrapleural administration approach. Direct peer to Randis's p53 Dry Gene Powder program and the only publicly known Japanese peer also targeting MPM with gene therapy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Randis Pharmaceutical Development Institute financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Randis Pharmaceutical Development Institute leadership team

Management profile

Number of profiles

Profiles1 record

Randis Pharmaceutical Development Institute funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Randis Pharmaceutical Development Institute M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Randis Pharmaceutical Development Institute

What does Randis Pharmaceutical Development Institute do?

Randis Pharmaceutical Development Institute conducts development of novel cancer gene therapy drugs (including a p53 Dry Gene Powder for malignant pleural mesothelioma) and provides contracted R&D services for powder inhalation formulations of low-molecular-weight compounds and nucleic acids targeting lung diseases. It also offers consulting services on Drug Delivery System (DDS) technology adoption, particularly for administration route optimization.

Is Randis Pharmaceutical Development Institute a public or private company?

Randis Pharmaceutical Development Institute is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Randis Pharmaceutical Development Institute founded?

Randis Pharmaceutical Development Institute was founded in 2023.

Where is Randis Pharmaceutical Development Institute based?

Randis Pharmaceutical Development Institute is headquartered in Nishiku, Japan, in the Asia region.

How does Randis Pharmaceutical Development Institute make money?

Three revenue lines are on record. Pharmaceutical R&D Services are the primary driver. The others are R&D Outsourcing Services and R&D Consulting Services.

Who are Randis Pharmaceutical Development Institute's main competitors?

Broad incumbents on record are Takara Bio Inc., Hovione, CMIC Holdings and Catalent. Emerging players are Aerogen, Curalogic and Arcturus Therapeutics. Direct peers are Vectura Group, Noile-Immune Biotech and AnGes, Inc..

Does Randis Pharmaceutical Development Institute have an API?

No public API is recorded for Randis Pharmaceutical Development Institute.

What industry is Randis Pharmaceutical Development Institute in?

Randis Pharmaceutical Development Institute's product category is Pharmaceutical R&D Services. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales